1. Is NGL Fine-Chem Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that NGL Fine-Chem Ltd is a average quality company.
2. Is NGL Fine-Chem Ltd undervalued or overvalued?
The key valuation ratios of NGL Fine-Chem Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
3. Is NGL Fine-Chem Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of NGL Fine-Chem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||12.8%||16.5%||18.5%||23.9%||21.1%||14.1%||18.1%||9.7%||37.2%||26.2%||-|
|Value Creation Index ⓘ||-0.1||0.2||0.3||0.7||0.5||0||0.3||-0.3||1.7||0.9||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||41.9%||12%||9%||3.6%||14%||34.8%||-0.7%||69.7%||23.4%||-|
|Adj EPS ⓘ||4.7||8.1||11.3||18.5||22.9||18.6||29||16.6||88.1||84.6||39.2|
|YoY Gr. Rt. %||-||72.1%||38.9%||63.1%||24.2%||-18.9%||56%||-42.7%||430%||-4%||-|
|BVPS (₹) ⓘ||32.4||39.7||53.1||71.6||96.2||116.6||149.1||163.8||251.6||334.4||341.3|
|Adj Net Profit ⓘ||2.9||5||7||11.4||14.2||11.5||17.9||10.3||54.5||52.3||24|
|Cash Flow from Ops. ⓘ||0||-0.3||7.5||8.4||9.9||22.4||8.9||19.6||26.6||12.7||-|
|Debt/CF from Ops. ⓘ||-567.8||-56.2||1.8||1.7||2.3||1.2||3.1||1.4||0.6||2.4||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||37.8%||29.8%||42.9%||-4%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||15.7||22.6||24.4||29.6||27.3||17.5||21.8||10.6||42.4||28.9||11.6|
|Op. Profit Mgn % ⓘ||13.6||14.3||16.9||22.8||25.6||19||21.1||15.2||29.8||20.7||9.1|
|Net Profit Mgn % ⓘ||5.3||6.4||7.9||11.8||14.2||10.1||11.7||6.8||21.1||16.4||8.4|
|Debt to Equity ⓘ||0.7||0.7||0.4||0.3||0.4||0.4||0.3||0.3||0.1||0.2||0|
|Working Cap Days ⓘ||147||138||152||160||187||198||167||184||132||166||218|
|Cash Conv. Cycle ⓘ||59||62||65||74||81||65||55||79||49||74||137|
Sales growth is growing at healthy rate in last 3 years 27.66%
Net Profit is growing at healthy rate in last 3 years 42.87%
Return on Equity has declined versus last 3 years average to 11.60%
Sales growth is not so good in last 4 quarters at -3.41%
|TTM EPS (₹)||39.2||35.6|
|TTM Sales (₹ Cr.)||287||298|
|BVPS (₹.) ⓘ||341.3||334.8|
|Reserves (₹ Cr.) ⓘ||208||204|
|From the Market|
|52 Week Low / High (₹)||1387.00 / 2935.00|
|All Time Low / High (₹)||0.40 / 3789.45|
|Market Cap (₹ Cr.)||1,024|
|Equity (₹ Cr.)||3.1|
|Face Value (₹)||5|
|Industry PE ⓘ||37.7|
NGL Fine-chem is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. It caters to various global companies to custom manufacture high quality pharmaceuticals with reliability and flexibility.
Its business is modelled around the changing customer demands and their ability to offer value-added innovative solutions to meet and even exceed these demands.
Utilizing its expertise in complex multi-stage organic synthesis, it continues to expand the product portfolio with new products.
It has established a strong presence in global pharmaceutical companies with its commitment to competitive prices, delivery schedules, international quality standards and constant technological upgradation.
NGL Fine-chem Ltd has a strong focus on developing intellectual property as a key differentiator and as a platform for further growth up the pharma value chain. It respect intellectual property and invest in developing it as a key growth driver for the future.
Product range of the company includes:
Pharmaceutical like Diminazene Aceturate, Diminazene Diaceturate, Homidium Chloride, Nitroxynil, Clorsulon, Homidium Bromide, Parvaquone, Carprofen, Buparvaquone and Isometamidium Chloride Hydrochloride for:
An ISO 9001:2000 accredited company